日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

BIZCHINA> Top Biz News
Profits up for flu vaccine makers
By Ding Qingfen (China Daily)
Updated: 2009-11-16 07:55

Profits up for flu vaccine makers

Primary school students receive injections of anti-H1N1 influenza medicine in Hunan province. GlaxoSmithKline (GSK) has received orders for 1.2 million packs of its anti-H1N1 influenza medicine, Relenza, from the Chinese government. [Asianewsphoto]

International pharmaceutical companies are cashing in on China's efforts to protect its people from the H1N1 pandemic with anti-influenza medicines.

GlaxoSmithKline (GSK), a leading international pharmaceutical company and China's largest by sales volume, received approval from the State Food and Drug Administration for its anti-H1N1 influenza medicine to enter the China market in July.

Since then, GSK has prepared 1.2 million packs of the anti-H1N1 influenza medicine called Relenza available for governments at all levels in China. The governments are storing the anti-virus in anticipation of a massive flu outbreak in coming months.

"GSK expects very strong demand for Relenza this year in China," Mark Reilly, general manager of GSK China, told China Business Weekly.

Profits up for flu vaccine makers

Chen Zhaorong, area medical manager at GSK China, also predicted that GSK will receive more orders in the months ahead.

"Compared with that from the other nations worldwide, China's orders are still small (for GSK)," Chen said.

Actually, the production capacity for Relenza is around 60 million packs. GSK has contracts in place to supply Relenza to over 60 economies. Of which, at least 10 percent of its new production have been allocated for developing nations.

But Chinese rules require that only governments can purchase the anti-H1N1 flu medicine. Relenza is still unavailable for sale to consumers.

As the weather turns colder, China is now bracing for a major H1N1 flu case outbreak. As of Nov 11, more than 62,871 cases were reported in 31 provinces, municipalities and autonomous regions of the Chinese mainland. About 32,000 cases were reported just since Oct 12.

Related readings:
Profits up for flu vaccine makers 8M+ Chinese inoculated with A(H1N1) flu vaccine
Profits up for flu vaccine makers Two died after inoculation of A(H1N1) flu vaccine
Profits up for flu vaccine makers Beijing to extend A(H1N1) flu vaccine inoculation
Profits up for flu vaccine makers H1N1 vaccine and common flu vaccine to merge

"Many regions are entering the traditional period for possible flu outbreaks, which will last for two to three months, and prevention and control work is becoming tougher," said Liang Wannian, vice director of the health emergency office under the Ministry of Health.

The Chinese government plans to allocate 1.09 billion yuan ($159.65 million) for prevention and treatment of the flu, including purchases of vaccinations, anti-viral medicines and medical instruments.

The huge investment is attracting global players like GSK. To meet the growing demand for anti-virals in China, GSK is considering investing in a manufacturing facility to produce Relenza for the country, said the GSK's Reilly, declining to elaborate.


(For more biz stories, please visit Industries)

   Previous page 1 2 Next Page  

主站蜘蛛池模板: 色婷在线 | 国内精品小视频 | 久久久女人| 国产区第一页 | av新天堂 | 亚洲一区二区综合 | 色偷偷噜噜噜亚洲男人 | 日日爱av | 日产精品久久久 | 91传媒在线观看 | 日韩mv欧美mv国产网站 | 日韩毛毛片 | 99久 | 中文字幕国产精品 | 亚洲精品久久久久国产 | 亚洲一区二区在线免费 | 午夜第一页| 亚洲tv在线观看 | 免费一级淫片 | 中文字幕免费播放 | 国产精品视频 | 午夜黄色在线 | 天天综合久久 | 久久午夜精品 | 综合婷婷 | 国产成人综合自拍 | 久久久久婷婷 | 亚洲精品美女 | 欧美 日韩 视频 | 精品不卡一区二区 | 四虎福利视频 | 亚洲一二三视频 | 久久6精品 | 日韩成人激情 | 欧美a区 | 中文字幕欧美视频 | 深爱五月激情五月 | 久久久久久久久网 | 97国产在线 | 国产福利99 | 性网站在线观看 |